North Huajin Chemical Industries Co Ltd

Huajin Chemical announced that its Vice President Yan Zenghui has recently been placed under investigation and subjected to detention measures by supervisory authorities. The company stated that it has made proper arrangements for the work previously handled by Yan Zenghui, and that other directors and senior executives are performing their duties as normal, with production and operations unaffected. It is not yet aware of the progress or conclusions of the investigation. According to the website of the Central Commission for Discipline Inspection and the National Supervisory Commission, Yan Zenghui is suspected of serious disciplinary and legal violations and is undergoing disciplinary review and supervisory investigation by the disciplinary inspection and supervision team of the Central Commission for Discipline Inspection and the National Supervisory Commission stationed at China North Industries Group Corporation. Yan Zenghui was appointed Vice President in September 2025 and directly holds 39,400 shares of the company. Huajin Chemical is mainly engaged in the production and sale of petrochemicals and chemical fertilizers, and expects to achieve a net profit attributable to the parent company of 350 million to 400 million yuan in the first half of 2026, turning from a loss to a profit year-on-year.

Tinavi Medical announced plans to acquire a 62% stake in Shanghai Orthopaedics, expected to constitute a major asset restructuring, with trading in its shares to resume tomorrow. Yongding Co.'s controlling subsidiary has received purchase orders for high-power laser chip products worth approximately 1.133 billion yuan over the past month. Xingyun Technology's wholly-owned subsidiary has signed a supplementary agreement for computing power services, increasing the contract value to 3.053 billion yuan, up 201.14% from the original agreement. Jiayun Technology shareholder Ruineng Co. plans to acquire an 18.31% stake through a negotiated transfer, and trading in the shares will resume. Lianchuang Electronics' controlling shareholder is set to change to Shouxian Xinqiao, and trading in the shares will resume. GigaDevice Chairman Zhu Yiming has proposed a buyback of A-shares worth between 1 billion and 2 billion yuan for cancellation, and plans to increase his holdings by no less than 1 billion yuan. Sinosun Technology is planning a change of control, and trading in its shares has been suspended. Zijin Mining's controlling subsidiary has terminated its acquisition of Union Gold and plans to subscribe for a 9.2% stake in the company. Huawen Media has had its delisting risk warning removed but will continue to be subject to other risk warnings, with its stock abbreviation changed to ST Huawen. Hailiang Co.'s controlling shareholder has received a commitment letter for an 860 million yuan shareholding increase loan. Huajin Co. Vice General Manager Yan Zenghui has been placed under investigation and subjected to detention measures. Hengrui Medicine's insulin degludec injection has been approved for marketing for the treatment of type 2 diabetes in adults, making it the first domestically developed long-acting insulin analogue in China.